AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
ANGOLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2026, which ended November 30, 2025. Fiscal Year 2026 Second Quarter Highlights Quarter Ended November 30, 2025 Pro Forma* YoY Growth Net Sales $
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
ANGOLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference at 9:0
HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $16
ANGOGold Moves Higher; US Private Sector Job Growth Tops Estimates
ANGOMedical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
ANGOAngioDynamics raised its fiscal 2025 sales outlook to $285M-$288M and boosted its adjusted EBITDA forecast, expecting stronger Med Tech revenue growth.
AngioDynamics Expects 2025 Adjusted EPS Loss Of $(0.31)-$(0.34) Compared To Prior Guidance Of $(0.34)-$(0.38) And Consensus Of $(0.37)
ANGOAngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M
ANGOAngioDynamics Q3 2025 Adj EPS $0.03 May Not Be Comparable To $(0.13) Estimate, Sales $72.00M Beat $70.30M Estimate
ANGOEarnings Scheduled For April 2, 2025
ANGOUncovering Potential: AngioDynamics's Earnings Preview
ANGO12 Health Care Stocks Moving In Thursday's Pre-Market Session
ANGOAngioDynamics Announces 35.5% Clot Reduction With AlphaVac F1885 System in Trial, Meeting Primary Endpoints In Pulmonary Embolism Treatment Published In The Journal Of The Society For Cardiovascular Angiography & Interventions Titled Novel Mechanical Aspi
ANGOHC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $15
ANGOHC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $14 Price Target
ANGOAngioDynamics Secures CE Mark Approval In Europe For AlphaVac F18⁸⁵ System
ANGO